Westminister, CO's Surefire Medical launched a drug delivery catheter for for direct-to-tumor embolization procedures. "Chemo- and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors.
Bina's algorithm for the detection of small insertions and deletions placed first in its class in the DREAM Mutation Calling Challenge, while its somatic single nucleotide variant tool took second in its subcategory.
The European unit of India's Glenmark Pharmaceuticals has applied to move into Phase I clinical trials for GBR 1302, a HER2xCD3 bispecific antibody that the company said in preclinical work demonstrated superiority over current antibody therapies against most HER2-positive cancers, including breast cancer.
By noticing a connection between developing human egg cells and tumor cells, researchers have developed a method of cancer drug delivery that could more selectively target the offending cells and keep healthy tissue safe from harm, possibly preserving fertility, as well.
China plans a public health campaign on cancer that over the next three years will see screening for early detection expanded by nearly one-third, spur new drug development and direct focus on prevention that covers smoking, China Daily reported.
The United Kingdom has opened up another front of its 100,000 Genomes Project. Having started off sequencing the genomes of people with rare diseases, the team behind the initiative are now ready to take aim at their other big target: cancer.
The American Society of Clinical Oncology unveiled its framework for assessing cancer drugs earlier this summer, breaking new ground in helping doctors size up competing treatments. Now, the National Comprehensive Cancer Network is going a few steps farther.
A pair of VC darlings have hooked up to speed the development of targeted cancer therapies. The deal sees Flatiron Health combine its oncology cloud system with blood test data from Guardant Health to give drug developers a platform on which they can identify molecular targets and support enrollment in clinical trials.
Cancer doctors at the famed Mayo Clinic have been up in arms about escalating prices of cancer drugs. Now they have recruited a bunch of colleagues and are trying to rile up the public in hopes of starting a patient-based grassroots movement.
The maker of the first MRI-guided radiation cancer therapy system, ViewRay, has raised more cash since it cancelled a planned $52 million IPO in April than it expected to raise in that offering. It's raised a total of $76.7 million--$26.7 million of that in connection with a reverse merger that it just completed on July 23 and another $50 million in debt from royalty investor CRG in late June.